Publications
Found 4 results
Filters: Author is M.S. Li [Clear All Filters]
, “Han Chinese patients with dopa-responsive dystonia exhibit a low frequency of exonic deletion in the GCH1 gene”, vol. 14, pp. 11185-11190, 2015.
, “Quantitative candidate gene association studies of metabolic traits in Han Chinese type 2 diabetes patients”, vol. 14, pp. 15471-15481, 2015.
, “Meta-analysis demonstrates no association between XRCC1 Arg399Gln polymorphism and bladder cancer risk”, vol. 13, pp. 9976-9985, 2014.
, “Meta-analysis demonstrates no association between p53 codon 72 polymorphism and prostate cancer risk”, vol. 10, pp. 2924-2933, 2011.
Coughlin SS and Hall IJ (2002). A review of genetic polymorphisms and prostate cancer risk. Ann. Epidemiol. 12: 182- 196.
http://dx.doi.org/10.1016/S1047-2797(01)00310-6
Guimaraes DP and Hainaut P (2002). TP53: a key gene in human cancer. Biochimie 84: 83-93.
http://dx.doi.org/10.1016/S0300-9084(01)01356-6
Henner WD, Evans AJ, Hough KM, Harris EL, et al. (2001). Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate 49: 263-266.
http://dx.doi.org/10.1002/pros.10021
PMid:11746272
Higgins JP and Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat. Med. 21: 1539-1558.
http://dx.doi.org/10.1002/sim.1186
PMid:12111919
Hollstein M, Sidransky D, Vogelstein B and Harris CC (1991). p53 mutations in human cancers. Science 253: 49-53.
http://dx.doi.org/10.1126/science.1905840
PMid:1905840
Hsing AW and Chokkalingam AP (2006). Prostate cancer epidemiology. Front. Biosci. 11: 1388-1413.
http://dx.doi.org/10.2741/1891
PMid:16368524
Huang SP, Wu WJ, Chang WS, Wu MT, et al. (2004). p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Canc. Epidemiol. Biomarkers Prev. 13: 2217-2224.
PMid:15598783
Jemal A, Siegel R, Xu J and Ward E (2010). Cancer statistics, 2010. CA Cancer J. Clin. 60: 277-300.
http://dx.doi.org/10.3322/caac.20073
PMid:20610543
Katkoori VR, Jia X, Shanmugam C, Wan W, et al. (2009). Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin. Cancer Res. 15: 2406-2416.
http://dx.doi.org/10.1158/1078-0432.CCR-08-1719
PMid:19339276
Klug SJ, Ressing M, Koenig J, Abba MC, et al. (2009). TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol. 10: 772-784.
http://dx.doi.org/10.1016/S1470-2045(09)70187-1
Leiros GJ, Galliano SR, Sember ME, Kahn T, et al. (2005). Detection of human papillomavirus DNA and p53 codon 72 polymorphism in prostate carcinomas of patients from Argentina. BMC Urol. 5: 15.
http://dx.doi.org/10.1186/1471-2490-5-15
PMid:16307686 PMCid:1314892
Lesko SM, Rosenberg L and Shapiro S (1996). Family history and prostate cancer risk. Am. J. Epidemiol. 144: 1041-1047.
PMid:8942435
Levine AJ (1997). p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
http://dx.doi.org/10.1016/S0092-8674(00)81871-1
Levine AJ, Momand J and Finlay CA (1991). The p53 tumour suppressor gene. Nature 351: 453-456.
http://dx.doi.org/10.1038/351453a0
PMid:2046748
Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, et al. (2000). Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 343: 78-85.
http://dx.doi.org/10.1056/NEJM200007133430201
PMid:10891514
Mechanic LE, Bowman ED, Welsh JA, Khan MA, et al. (2007). Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors. Cancer Epidemiol. Biomarkers Prev. 16: 214-222.
http://dx.doi.org/10.1158/1055-9965.EPI-06-0790
Pegoraro RJ, Moodley M, Rom L, Chetty R, et al. (2003). P53 codon 72 polymorphism and BRCA 1 and 2 mutations in ovarian epithelial malignancies in black South Africans. Int. J. Gynecol. Cancer 13: 444-449.
http://dx.doi.org/10.1046/j.1525-1438.2003.13333.x
PMid:12911720
Peters JL, Sutton AJ, Jones DR, Abrams KR, et al. (2006). Comparison of two methods to detect publication bias in meta-analysis. JAMA 295: 676-680.
http://dx.doi.org/10.1001/jama.295.6.676
PMid:16467236
Quinones LA, Irarrazabal CE, Rojas CR, Orellana CE, et al. (2006). Joint effect among p53, CYP1A1, GSTM1 polymorphism combinations and smoking on prostate cancer risk: an exploratory genotype-environment interaction study. Asian J. Androl. 8: 349-355.
http://dx.doi.org/10.1111/j.1745-7262.2006.00135.x
PMid:16625286
Ricks-Santi L, Mason T, Apprey V, Ahaghotu C, et al. (2010). p53 Pro72Arg polymorphism and prostate cancer in men of African descent. Prostate 70: 1739-1745.
PMid:20593380 PMCid:3057117
Shepherd T, Tolbert D, Benedetti J, Macdonald J, et al. (2000). Alterations in exon 4 of the p53 gene in gastric carcinoma. Gastroenterology 118: 1039-1044.
http://dx.doi.org/10.1016/S0016-5085(00)70356-8
Suzuki K, Matsui H, Ohtake N, Nakata S, et al. (2003). A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J. Biomed. Sci. 10: 430-435.
http://dx.doi.org/10.1007/BF02256434
PMid:12824702
Tsai MH, Lin CD, Hsieh YY, Chang FC, et al. (2002). Prognostic significance of the proline form of p53 codon 72 polymorphism in nasopharyngeal carcinoma. Laryngoscope 112: 116-119.
http://dx.doi.org/10.1097/00005537-200201000-00020
PMid:11802048
Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, et al. (2007). STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology 18: 805-835.
http://dx.doi.org/10.1097/EDE.0b013e3181577511
PMid:18049195
Viechtbauer W (2007). Confidence intervals for the amount of heterogeneity in meta-analysis. Stat. Med. 26: 37-52.
http://dx.doi.org/10.1002/sim.2514
PMid:16463355
Wang YC, Chen CY, Chen SK, Chang YY, et al. (1999). p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin. Cancer Res. 5: 129-134.
PMid:9918210
Wu HC, Chang CH, Chen HY, Tsai FJ, et al. (2004). p53 gene codon 72 polymorphism but not tumor necrosis factor-alpha gene is associated with prostate cancer. Urol. Int. 73: 41-46.
http://dx.doi.org/10.1159/000078803
PMid:15263792
Wu WJ, Kakehi Y, Habuchi T, Kinoshita H, et al. (1995). Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers. Jpn. J. Cancer Res. 86: 730-736.
http://dx.doi.org/10.1111/j.1349-7006.1995.tb02461.x
Zhou Y, Li N, Zhuang W, Liu GJ, et al. (2007). P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int. J. Cancer 121: 1481-1486.
http://dx.doi.org/10.1002/ijc.22833
PMid:17546594
Zintzaras E and Ioannidis JP (2005). Heterogeneity testing in meta-analysis of genome searches. Genet. Epidemiol. 28: 123-137.
http://dx.doi.org/10.1002/gepi.20048
PMid:15593093